Ali Behbahani

The Medicines Co. is a biopharmaceutical company, which focuses on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on acute and intensive care hospitals worldwide. The firm markets its brands Angiomax, Cleviprex, injectable emulsion, Ionsys, Kengreal, Minocin for injection, and Orbactiv. The company was founded by Clive A. Meanwell, Helmut Giersiefen, John W. Villiger and T. Scott Johnson on July 31, 1996 and is headquartered in Parsippany, NJ.

Formerly known as Lincoln Capital Fixed Income Management Co. LLC, Lehman Brothers Asset Management LLC (LBAM) is a wholly owned subsidiary of Lehman Brothers Holdings, Inc. (NYSE:LEH)

Solace Therapeutics, Inc. develops non-surgical treatments for common bladder disorders. It offers medical devices for stress urinary incontinence, overactive bladder, male voiding dysfunction, and lower urinary tract symptoms. The company was founded by Kevin G. Connors in 2002 and is headquartered in Framingham, MA.

Rotation Medical, Inc. develops treatment of rotator cuff disease. It includes a bioinductive implant and a set of disposable arthroscopic instruments that has been shown to heal tendons by inducing the growth of new tendon-like tissue. The company was founded by Thomas R. Hektner in 2009 and is headquartered in Plymouth, MN.

Ivantis, Inc. develops technology to treat ophthalmic diseases. The firm develops solutions for glaucoma and offers an intracanalicular scaffold or implantable device that relieves high intraocular pressures in patients. It provides its solutions for use in clinical trials to ophthalmology specialists. Ivantis was founded in 2007 and is headquartered in Irvine, CA.

Ocutherix, Inc. operates as a medical device incubator which focuses on novel medical technologies. The firm serves the ophthalmology, cardiology, mobile health, orthopedics, neurology, pulmonology and metabolic clinical solutions. The company was founded by Robert E. Atkinson in 2005 and is headquartered in Stillwater, MN.

Morgan Stanley Venture Partners (MSVP) is a venture capital firm subsidiary of Morgan Stanley Investment Management Merchant Banking, which is ultimately owned by Morgan Stanley (NYSE: MWD) founded in 1986.The firm is headquartered in New York.

New Enterprise Associates LLC (New Enterprise Associates) is a venture capital firm founded in 1977. The firm headquartered in Menlo Park, California.

Adaptimmune Ltd. develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous and infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was founded by Bent K. Jakobsen, James Julian Noble and Helena Katrina Tayton-Martin in 2008 and is headquartered in Oxford, the United Kingdom.

ClarVista Medical, Inc. operates as a medical device company which focuses on the novel solutions in ophthalmology. It develops the harmoni modular intra-ocular lens systems to optimize vision in the setting of cataract surgery. The company was founded by Paul McLean and Robert E. Atkinson in 2012 and is headquartered in Aliso Viejo, CA.

Cardionomic, Inc. engages in the development of medical devices. The company was founded in 2011 and is headquartered in New Brighton, MN.

Oyster Point Pharma, Inc. engages in the development and commercialization of pharmaceutical therapies to treat ocular surface diseases. Its product candidate, OC-01, is a nicotinic acetylcholine receptor agonist, which is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. The company was founded by Michael and is Ackermann in June 30, 2015 headquartered in Princeton, NJ.

New Enterprise Associates LLC is an alternative investment manager. The private company is based in Timonium, MD. The company was founded in 1978 by Chuck Newhall, C. Richard Kramlich.

Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.

858 Therapeutics, Inc. operates as a pharmaceutical company. The company was founded in 2019 and is headquartered in San Diego, CA.

Stablix, Inc. is a biotechnology company based in New York, NY. The company is focused on establishing a new paradigm for tackling diverse diseases by harnessing the power of the body's own cellular machinery through targeted protein stabilization. Stablix's restored™ platform generates heterobifunctional small molecules (restoracs™) that selectively recruit active deubiquitinases (dubs) to target proteins for precise removal of ubiquitin to restore protein function. The company is currently advancing its lead programs towards clinical studies. The company's platform is based on the work of Henry Colecraft, Ph.D., professor of physiology and cellular biophysics, and professor of pharmacology, Columbia University Irving Medical Center. Stablix was founded in June 2021 with a $63 million series A led by founding investor Versant Ventures with New Enterprise Associates (NEA), Cormorant Asset Management, Euclidean Capital, and Alexandria Venture Investments. Stuart Anthony Kingsley has been the CEO of the company since 2022.

Tune Therapeutics, Inc. is a genetic medicine company based in Durham, NC. Tune Therapeutics is pioneering a new therapeutic modality with its versatile and powerful tempo epigenomic control platform. The platform has the potential to fine-tune any gene network and unlock the full power and potential of regenerative medicine. The company is driving through an inflection point in the history of genetic medicine by addressing thousands of common and complex diseases for which no curative treatment is available. Tune Therapeutics pioneers next-generation genetic therapies by exploring epigenomic control for discovering novel targets that are inaccessible to other approaches. The company was founded in 2020 by Fyodor Urnov, Akira Matsuno, Charles A. Gersbach. The CEO is Matt Kane.

Spyglass Ophthalmics, Inc. develops products for vision and eye care. The company was founded by Malik Y. Kahook and Glenn Sussman and is headquartered in Mission Viejo, CA.

Launchpad Therapeutics, Inc. develops novel therapeutics.